Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Next Previous
Trial Profile

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Anastrozole/testosterone (Primary) ; Elacestrant (Primary) ; Endoxifen (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary)
  • Indications Breast cancer; Ductal carcinoma
  • Focus Therapeutic Use
  • Acronyms RECAST DCIS; RECAST DCIS Platform Trial; RECAST Trial
  • Sponsors Quantum Leap Healthcare Collaborative

Most Recent Events

  • 03 Nov 2023 New trial record
  • 30 Oct 2023 According to a Quantum Leap Healthcare Collaborative media release, company announced the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. The study is open to enrollment with each investigational agent arm expected to enroll up to 110 patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top